Ampio Pharma stock plummets 55% after negative late-stage trial results
Ampio Pharmaceuticals Inc. shares sank 54.8% in pre-market trade Thursday after a phase 3 trial for its osteoarthritis pain treatment missed its primary endpoint. Shares of Ampio rose 46.9% over the last three months, compared with a 0.33% rise in the S&P 500 .
Читать дальше...